Clinical trials: Elderly Patients
Non-Small Cell Lung Cancer
Trial of Pemetrexed or Pemetrexed With Gemcitabine for Patients With Advanced Lung Cancer Who Are Not Eligible for Platinum-Based Chemotherapy and Have Not Previously Been Treated With Chemotherapy
This study is for elderly patients who haven't been given prior chemotherapy or for patients who cannot be treated with platinum based chemotherapy.
- Trial name
- NCT00489983
- Testing
- pemetrexed, gemcitabine
- Where
- 3 sites in Germany, Italy and 1 more
- Volunteers
- 91 people
- Sponsor
- Eli Lilly and Company
Leukemia, Myeloid, Acute, Hematologic Neoplasms
Trial of Pimasertib in Hematological Malignancies
This is an open-label, multi-center, dose-escalation trial of pimasertib (MSC1936369B) in blood and bone marrow cancers. The trial will be conducted in two parts: Part 1 (safety run-in period): Will determine the maximum…
- Trial name
- NCT00957580
- Testing
- Pimasertib
- Where
- 9 sites in United States, France
- Volunteers
- 81 people
- Sponsor
- EMD Serono
Unstable Angina
Efficacy and Safety of Salvianolate Injection in Elderly Patients With Unstable Angina Pectoris
This parallel, double blind, randomized, controlled, multi-center study will evaluate the efficacy and safety of salvianolate injection in elderly patients with unstable angina pectoris.
- Trial name
- NCT03037047
- Testing
- 0.9% Sodium Chloride Injection, salvianolate injection
- Where
- China
- Volunteers
- 320 people
- Sponsor
- Green Valley Group of China
Chondral Defect, Articular Cartilage Defect
A Study of MACI in Patients Aged 17 to 65 Years With Symptomatic Chondral or Osteochondral Defects of the Ankle
The objective of this study is to demonstrate the superiority of MACI (autologous cultured chondrocytes on porcine collagen membrane) versus Bone Marrow Stimulation in the treatment of patients aged 17 to 65 years with…
- Trial name
- MASCOT (NCT06915233)
- Testing
- autologous cultured chondrocytes on porcine collagen membrane, Bone Marrow Stimulation
- Where
- 12 sites in United States
- Volunteers
- 309 people
- Sponsor
- Vericel Corporation
Accidental Falls, Fractures
Clinical Evaluation of a Wireless Monitoring Device to Reduce Falls in the Elderly and Others at High Risk of Falling
Falls are a public health problem of significant social and economic significance. No primary intervention devices have been shown to be effective in reducing falls and associated injuries.
- Conditions
- Accidental Falls, Fractures, Injuries
- Trial name
- NCT00249743
- Testing
- FallSaver (formerly called NOCwatch)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- NOCwatch International
Leukemia, Myeloid, Acute
Volasertib in Combination With Low-dose Cytarabine in Patients Aged 65 Years and Above With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy (POLO-AML-2)
To investigate the efficacy, safety, and pharmacokinetics of intravenous volasertib + subcutaneous low dose cytarabine in patients >= 65 years of age with previously untreated acute myeloid leukaemia, ineligible for intensive…
- Trial name
- NCT01721876
- Testing
- Volasertib, Cytarabine
- Where
- 122 sites in United States, Argentina and 23 more
- Volunteers
- 666 people
- Sponsor
- Boehringer Ingelheim
Short Bowel Syndrome
A Study of Teduglutide in Japanese Children With Short Bowel Syndrome Aged 4 Months or Older
The main aims of the study are to check for side effects from teduglutide. Participants will receive a daily injection of teduglutide just under the skin (subcutaneous) for 24 weeks. Then they are followed up for another 4 weeks.
- Trial name
- NCT05027308
- Testing
- Teduglutide
- Where
- 6 sites in Japan
- Volunteers
- 3 people
- Sponsor
- Takeda
Non-Valvular Atrial Fibrillation
A Study to Collect Information on the Characteristics of Elderly Belgian Patients With NVAF That Are Treated With a NOAC for This Indication With a Special Focus on Their Fear of Bleeding While Using a NOAC vs the Clinical Benefit of a NOAC of Thrombosis/Stroke Prevention.
Atrial fibrillation is a heart condition that causes an abnormal and fast heart rate. For people with non-valvular atrial fibrillation (NVAF), this is caused by problems such as high blood pressure and diabetes.
- Trial name
- BELANCE (NCT04722679)
- Testing
- Non-VKA Oral Anticoagulants (NOAC)
- Where
- Belgium
- Volunteers
- 103 people
- Sponsor
- Bayer
Attention Deficit Hyperactivity Disorder
Characterization of Dermal Reactions in Pediatric Patients With ADHD Using DAYTRANA
This is a study designed to characterize the dermal response of DAYTRANA. Subjects will visit the study site over a period of approximately 14 weeks.
- Trial name
- NCT00434213
- Testing
- Daytrana
- Where
- 29 sites in United States
- Volunteers
- 309 people
- Sponsor
- Noven Therapeutics
Hypertension
Telmisartan Compared With Enalapril in Elderly Patients With Blood Hypertension
Study to assess the efficacy and tolerability of Telmisartan 40-80 mg once daily compared with enalapril 10-20 mg once daily in elderly patients with arterial hypertension.
- Trial name
- NCT02177461
- Testing
- Telmisartan, Enalapril, Clonidine
- Volunteers
- 374 people
- Sponsor
- Boehringer Ingelheim
Idiopathic Infertility, Infertility Unexplained
Biological Aging Hallmarks-Guided Integrative TCM and Conventional Medicine in Post-Treatment Unexplained Female Infertility
The goal of this clinical trial is to determine whether telomere profiling and other biological aging hallmarks can help identify underlying mechanisms of persistent infertility in women with post-treatment unexplained…
- Conditions
- Idiopathic Infertility, Infertility Unexplained, Infertility (IVF Patients), Infertility Assisted Reproductive Technology
- Trial name
- TECMI (NCT07404969)
- Testing
- 1. Aging Hallmarks Biomarker Profiling (Telomere-Based), 2. Integrative Botanical and Nutraceutical Intervention, 3. Natural Conception or Assisted Reproductive Technologies
- Where
- Switzerland
- Volunteers
- 15 people
- Sponsor
- BEYOND GENOMiX SA, AG, Ltd
Atopic Dermatitis
IB/IIa Study of MG-K10 in Adolescent Moderately Severe Patients
This study was designed to reflect the safety pharmacokinetics and preliminary efficacy of MG-K10 Humanized Monoclonal Antibody Injection in adolescent patients 12-18 weeks of age with moderate to severe atopic dermatitis…
- Trial name
- NCT06765005
- Testing
- MG-K10
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Shanghai Mabgeek Biotech.Co.Ltd
Urinary Bladder, Overactive
Local, Open-Label, Extension Trial Of The Efficacy And Safety Of Fesoterodine In Elderly Patients With Overactive Bladder
This is an open-label extension study intended for subjects who have previously completed study A0221045 (fesoterodine in elderly OAB patients) and who have been recommended by the investigator as being suitable for the extended…
- Trial name
- NCT01054222
- Testing
- Fesoterodine
- Where
- 3 sites in Portugal
- Volunteers
- 31 people
- Sponsor
- Pfizer
Asthma
A Study Comparing the Efficacy and Safety of CHF 1535 (BDP +FF) Inhalation Powder, Administered Via the NEXT Inhaler, Versus CHF 1535 (BDP +FF), Administered Via a pMDI, in Moderate to Severe Asthma
To demonstrate that CHF 1535 via NEXT DPI (beclomethasone dipropionate + formoterol fumarate 100 + 6 μg), 1 inhalation or 2 inhalations twice daily, for 12 weeks is non-inferior to the corresponding dose of CHF 1535 via HFA-134a…
- Trial name
- NCT00862394
- Testing
- BDP/Formoterol Next DPI, Foster
- Where
- Germany
- Volunteers
- 783 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Atopic Dermatitis
A Study to Determine the Safety and Tolerability of Dupilumab (REGN668/SAR231893) in Patients Aged ≥6 to <18 Years With Atopic Dermatitis (Eczema)
The primary objective of the study is to characterize the safety and pharmacokinetics (PK) of dupilumab in pediatric patients with moderate-to-severe atopic dermatitis (AD) (for adolescents ≥12 to <18 years of age) or severe AD…
- Trial name
- NCT02407756
- Testing
- Dupilumab
- Where
- 26 sites in Canada, Czechia and 4 more
- Volunteers
- 78 people
- Sponsor
- Regeneron Pharmaceuticals
Hospitalized Elderly
A Trial of an Oral Nutritional Supplement in Older Hospitalized Patients - NOURISH Study
Evaluate effects of an oral nutritional supplement on healthcare outcomes in older hospitalized adults. Also referred to as the NOURISH Study - Nutrition effect On Unplanned Readmissions and Survival in Hospitalized patients.
- Trial name
- NCT01626742
- Testing
- Ready to Drink Flavored Beverage, Ready to drink flavored beverage w/ AN 777
- Where
- 119 sites in United States, Puerto Rico
- Volunteers
- 652 people
- Sponsor
- Abbott Nutrition
Iron-deficiency
Study of the Prevalence of Iron Deficiency in Elderly Patient in Hospital Environment
Iron deficiency is defined by insufficient tissue iron stores and anemia is the ultimate stage of iron deficiency. Anemia should never be neglected in an elderly subject because it is associated with an increase in mortality, but…
- Trial name
- CARENFERPA (NCT05514951)
- Testing
- Blood sampling
- Where
- 16 sites in France
- Volunteers
- 888 people
- Sponsor
- Vifor Pharma
Asthma
Pediatric Study to Evaluate Treatment of Persistent Moderate or Severe Asthma With the Association Fluticasone 250 mcg/Dose and Salmeterol 50 mcg/Dose - ADERE PROJECT
Prospective, parallel-group, randomized study to evaluate the compliance to the treatment of children aged between 6 and 14 years old with persistent moderate or severe asthma, receiving the association Fluticasone 250 mcg/dose…
- Trial name
- ADERE (Ped) (NCT01476059)
- Testing
- Telephone follow-up, No telephone follow-up
- Volunteers
- 472 people
- Sponsor
- GlaxoSmithKline
Plaque Psoriasis, Psoriatic Arthritis
A Study of Ixekizumab (LY2439821) in Participants Aged ≥18 Years With Moderate-to-Severe Plaque or Active Psoriatic Arthritis in India
The main purpose of this study is to investigate the safety and tolerability of ixekizumab in participants in India with moderate-to-severe plaque psoriasis (PsO) or active psoriatic arthritis (PsA)
- Trial name
- NCT05855967
- Testing
- Ixekizumab
- Where
- 14 sites in India
- Volunteers
- 250 people
- Sponsor
- Eli Lilly and Company
Sickle Cell Disease
A Study of Intravenous L-Citrulline in Patients Aged 6-21 Years Old With Sickle Cell Disease Presenting to Emergency Departments in Acute Vaso-Occlusive Crisis
This study is being done to learn more about a possible new treatment for pain episodes (called vaso-occlusive crises or VOCs) in children, teens, and young adults with sickle cell disease (SCD).
- Trial name
- NCT06989567
- Testing
- L-citrulline
- Where
- 6 sites in United States
- Volunteers
- 120 people
- Sponsor
- Asklepion Pharmaceuticals, LLC